Compare · COEP vs GILD
COEP vs GILD
Side-by-side comparison of Coeptis Therapeutics Holdings Inc. (COEP) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COEP and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 1911.9x COEP ($102.1M).
- Over the past year, COEP is up 6.3% and GILD is up 27.2% - GILD leads by 20.8 points.
- COEP has been more active in the news (8 items in the past 4 weeks vs 6 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 0 for COEP).
- Company
- Coeptis Therapeutics Holdings Inc.
- Gilead Sciences Inc.
- Price
- $16.27+0.81%
- $156.22-0.76%
- Market cap
- $102.1M
- $195.13B
- 1M return
- +46.05%
- +3.48%
- 1Y return
- +6.34%
- +27.19%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 1992
- News (4w)
- 8
- 6
- Recent ratings
- 0
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest COEP
- SEC Form 4 filed by Coeptis Therapeutics Holdings Inc.
- Chief Executive Officer Halabu David Elias converted options into 19,737 shares (SEC Form 4)
- Director Sohn Adam Craig converted options into 1,370 shares (SEC Form 4)
- Director Fuerst Bryan Eric converted options into 1,370 shares (SEC Form 4)
- Director Cooper Kenneth Lyle converted options into 1,370 shares (SEC Form 4)
- Chief Technology Officer Harris Jeffery Keeslar converted options into 12,444 shares (SEC Form 4)
- Chief Financial Officer Cogley Brian converted options into 4,112 shares, increasing direct ownership by 18% to 26,612 units (SEC Form 4)
- Amendment: Chief Marketing Officer Schadel Christopher Ryan bought $3,920 worth of shares (1,000 units at $3.92) and converted options into 3,169 shares (SEC Form 4)
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)